Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patientsMesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Cytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsKIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisInhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaChronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical featuresAdvanced systemic mastocytosis: from molecular and genetic progress to clinical practiceCancer stem cells in basic science and in translational oncology: can we translate into clinical application?Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcomaThe basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosisIdentification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulationExpression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission durationEfficacy and Safety of Midostaurin in Advanced Systemic MastocytosisNilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft modelTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaTKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CMLMolecular and immunological characterization of arginine kinase from the Indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen.Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia.Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy.A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain.Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition.Characterization of folded recombinant Der p 5, a potential diagnostic marker allergen for house dust mite allergy.Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes.Autoimmune thrombocytopenia in non-Hodgkin's lymphomas.Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model.Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccinationExpression of homing receptors and related molecules on human mast cells and basophils: a comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques.Mast cell activation syndrome: Proposed diagnostic criteria.Mast cell activation syndromes: definition and classification.BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Clinical and biologic diversity of leukemias occurring in patients with mastocytosis.Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposalSuccessful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation.Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.Interleukin 3 activates human blood basophils via high-affinity binding sites.
P50
Q22008550-09004219-6425-4CA2-AA28-CE93C7B24634Q26746104-AFF3A8B4-84CB-4EC5-BED5-05E8BBDF3259Q26778929-F7D21AA7-36E5-4C89-88BE-174944619432Q26830207-B693D0FB-4547-4A0F-85E5-E381FB7BD63EQ27004027-D161BB8B-DCE3-483E-A439-2B3CD0895B0BQ27026581-CA0BEAFA-6FDE-44A5-B20B-01C4526EB6B2Q28068458-A137AF63-D11B-42FD-B765-25479CE0FBC3Q28081844-8CB5881C-D81C-4E81-8392-685ABCA90AC1Q28182227-624A7B7E-6740-473E-9F31-6F364F48B5F4Q28187816-7CE65C12-2724-402D-AF83-F24A2456323EQ28251388-5FA506B0-FBC1-4B4A-8D42-55A4382B2EEAQ28252822-17C7A5FE-922F-4F4C-B20F-0C0526155AE3Q28263954-09EA48A0-7C52-4BEF-8890-5B6395665FF4Q28314922-C1353682-8B9C-4978-8F1D-15FEE97B8C84Q28480622-1CF4470C-7057-4C00-9CAA-8AC4C739D6A7Q28828739-A7F00459-1465-42DF-B0D6-B02529F1BDBBQ29617201-73E625A0-876D-4679-B3B3-7FC275734DD4Q30357188-F3A3F257-19FF-4385-93E5-C0D80ECA36C3Q30754183-A768D7DD-15AD-411B-B18F-0705DB1716F0Q30859697-461BBA5C-BC5D-4389-A1EB-0F33A555F438Q31049436-3FDBC400-17DC-4907-B49D-0A3F8B10E161Q31815273-29AA9869-63F9-42F7-8099-0C11FFE971BAQ31948966-2F7AEFDC-425C-4777-9C50-875002358623Q33339846-4D2E0E0F-0272-4C33-8FA3-8DEADB1C8D14Q33373120-699EC97D-9809-4D46-B7C3-9BA92A94F3E3Q33378695-511DE17C-B8B1-4858-AFCD-70B0DAE60A13Q33412532-9D76B656-49CF-4E0C-B921-86F46116EE99Q33881730-B8CAF192-D044-4FD4-98B9-B713FA8CB4BAQ33883053-38BF7747-86D0-4C1B-993C-26518BD3BD29Q33883709-B6EA5D3A-0677-42D3-92CE-5AA0875478ADQ34024510-11500E87-2090-49C4-B9ED-A7B558F948EAQ34035582-1BC92096-F118-4DFD-943E-C0C28425AC84Q34048020-AFFBCC5D-440D-4F6C-B954-50FBA762E6E1Q34066643-CC95FC5E-8340-4894-87D2-CA44A646F817Q34123890-E56AC140-94BC-4AC7-BD03-3D9F057B2C4AQ34133511-D49B3D0F-1916-4779-98A6-B53F41ED10ECQ34137971-2A4D03E1-5961-4CCF-886F-EEB742A59993Q34189131-8E0E20FD-9E6D-4F7D-904B-B87CAF36CC92Q34264299-6D17890C-177F-4505-A29C-12AF292B61E9Q34291889-2F6D70CB-2DEC-473C-9E65-EC892D182B9F
P50
description
onderzoeker uit Oostenrijk
@nl
researcher
@en
ricercatore
@it
österreichischer Hämatologe und Stammzellforscher
@de
հետազոտող
@hy
name
Peter Valent
@ast
Peter Valent
@de
Peter Valent
@en
Peter Valent
@es
Peter Valent
@nl
Peter Valent
@sl
type
label
Peter Valent
@ast
Peter Valent
@de
Peter Valent
@en
Peter Valent
@es
Peter Valent
@nl
Peter Valent
@sl
prefLabel
Peter Valent
@ast
Peter Valent
@de
Peter Valent
@en
Peter Valent
@es
Peter Valent
@nl
Peter Valent
@sl
P227
P106
P1412
P19
P21
P214
8937147270441235700001
P227
1112048979
P27
P31
P496
0000-0003-0456-5095
P569
1962-10-09T00:00:00Z
P735
P7859
viaf-8937147270441235700001